Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Hum Vaccin Immunother ; 16(3): 499-505, 2020 03 03.
Artículo en Inglés | MEDLINE | ID: mdl-31642729

RESUMEN

In Hong Kong, universal varicella vaccination was introduced in July 2014 with a two-dose schedule but the vaccines had been available in the private market since 1996. With data from varicella notification and surveys on immunization coverage, we used the screening method to estimate dose-specific varicella vaccine effectiveness (VE) among preschool children in Hong Kong before universal vaccination. We estimated the VE of one- and two-dose varicella vaccination against all notified varicella as 69.4% (95% confidence interval (95% CI) 69.5-71.2) and 93.4% (95% CI 91.7-94.7), respectively. We found that VE did not decrease with time since receipt. Varicella vaccine was more effective against complications (85.4% [95% CI 48.8-95.8] for one dose and 100% [95% CI -Inf to 100] for two doses) and against hospital admission (75.2% [95% CI 53.4-86.8] for one dose and 93.1% [95% CI 47.1-99.1] for two doses). Lower protection of one-dose varicella vaccine resulted in breakthrough varicella. Under universal vaccination, second-dose varicella vaccine (given as combined measles, mumps, rubella and varicella vaccine) was first scheduled for children when they reach primary one (about 6 years of age) and was recently advanced to 18 months of age. Shortening the interval between the first dose and second dose of varicella vaccination should reduce breakthrough varicella and outbreaks in preschool.


Asunto(s)
Varicela , Paperas , Varicela/epidemiología , Varicela/prevención & control , Vacuna contra la Varicela , Preescolar , Hong Kong/epidemiología , Humanos , Esquemas de Inmunización , Lactante , Vacuna contra el Sarampión-Parotiditis-Rubéola , Vacunación , Vacunas Combinadas
2.
Int J Infect Dis ; 98: 51-58, 2020 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-32579906

RESUMEN

BACKGROUND: Hong Kong, a Special Administrative Region of China, recorded its first confirmed coronavirus disease 2019 (COVID-19) case on 23 January 2020. We reviewed the case epidemiology and the various public health measures implemented from January to May 2020. METHODS: The epidemiological and clinical characteristics of the cases recorded in different phases of the epidemic were described and compared, and the effectiveness of the public health measures implemented were reviewed using the changes in the daily number of confirmed cases and the interval from symptom onset to hospital admission. RESULTS: Between January and May 2020, 1084 confirmed COVID-19 cases were reported, about 70% of which had a history of travel during the incubation period. The case fatality ratio was 0.4%. The local epidemic progressed through four phases: (1) preparedness and imported infection from mainland China, (2) local transmission, (3) imported infection from overseas countries associated with local transmission, and (4) controlled imported infection with limited local transmission, with an eventual reduction of the daily case number and minimization of the onset-to-admission interval. Various public health measures, including enhanced surveillance, border control, and social distancing, were introduced in phases in response to the prevailing local and global situations. DISCUSSION: The overall containment strategy in Hong Kong led to a stabilization of the number of cases and the absence of a community-wide outbreak during the 4.5 m after the first case was reported. This strategy of containment might serve as an example for future planning of preparedness and response against novel infectious agents.


Asunto(s)
Betacoronavirus , Infecciones por Coronavirus/epidemiología , Neumonía Viral/epidemiología , Adolescente , Adulto , Anciano , COVID-19 , Niño , Preescolar , Enfermedades Transmisibles Importadas , Brotes de Enfermedades/prevención & control , Femenino , Hong Kong/epidemiología , Hospitalización , Humanos , Lactante , Recién Nacido , Masculino , Persona de Mediana Edad , Pandemias , Salud Pública , SARS-CoV-2 , Viaje , Enfermedad Relacionada con los Viajes , Adulto Joven
3.
Hum Vaccin Immunother ; 15(1): 97-101, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-30148689

RESUMEN

The 2017/18 winter influenza season in Hong Kong started in early January 2018, predominated by influenza B/Yamagata. We collaborated with private medical practitioners of our sentinel surveillance system to collect respiratory specimens and clinical information from patients with influenza-like illness for estimation of the influenza vaccine effectiveness (VE) using the test-negative case-control design. We found that the overall VE was 59.1% (95%CI 41.1 to 71.8%) against all influenza and 53.5% (95%CI 35.4 to 74.6%) against influenza B. Seasonal influenza vaccine provided moderate to good protection against laboratory-confirmed influenza infection at primary care level in Hong Kong in the 2017/18 winter influenza season.


Asunto(s)
Vacunas contra la Influenza/inmunología , Gripe Humana/prevención & control , Atención Primaria de Salud , Potencia de la Vacuna , Adolescente , Adulto , Anciano , Estudios de Casos y Controles , Niño , Preescolar , Femenino , Hong Kong/epidemiología , Hospitalización , Humanos , Lactante , Vacunas contra la Influenza/administración & dosificación , Gripe Humana/epidemiología , Masculino , Persona de Mediana Edad , Vigilancia de Guardia , Vacunación/estadística & datos numéricos , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA